Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.57 - $33.33
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.60M
Market Cap
$1.93B
Enterprise Value$2.69B
Total Cash (Recent Filing)-$178.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.27
Next Earnings
May 13, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding145,215,400
10 Day Avg. Volume2,098,561
30 Day Avg. Volume1,601,483
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.68
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.45
Forecast
1Y Price Target
$39.09Price Target Upside211.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Denali Therapeutics News
PremiumCompany Announcements
Denali Therapeutics Begins BLA Submission for Tividenofusp Alfa
PremiumCompany Announcements
Denali Therapeutics Discontinues DNL343 ALS Trial---
Bulls Say, Bears Say
Bulls Say
Financial StabilityDenali has cash of approximately $1.2 billion, which should take the company into 2028.
Regulatory ApprovalDenali announced it had initiated the BLA submission for accelerated approval of its lead asset tividenofusp alfa (tivi) in Hunter syndrome.
Therapeutic PotentialThere is significant potential for tivi to address both neurologic and systemic symptoms of Hunter syndrome, unlike the current standard-of-care option Elaprase, which does not cross the blood–brain barrier.
Bears Say
Clinical Trial SetbacksDNL343 did not demonstrate a treatment effect on neurofilament light (NfL), a biomarker of neuronal damage.
Competitive ThreatsCompetitive Sanfilippo drug, RARE's UX111, could gain significant market share ahead of any DNL126 launch upon a successful outcome.
Pipeline ChallengesThe active treatment extension in Regimen G will be discontinued.
---
Ownership Overview
9.11% Insiders
31.93% Mutual Funds
0.02% Other Institutional Investors
43.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $10.57 and its highest was $33.33 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $1.93B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 26 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.129.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 145,215,400 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -10.968%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
---
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.09 (211.47% Upside)
$39.09 (211.47% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 354.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.17%
12-Months-Change
Fundamentals
Return on Equity
-37.40%
Trailing 12-Months
Asset Growth
19.09%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases, such as Alzheimer's, Parkinson's, and ALS. The company operates in the biotechnology sector, leveraging its expertise in the biology of neurodegeneration to create a diverse pipeline of product candidates. Denali's core services include the development of small molecules, antibodies, and other therapeutic modalities aimed at addressing the underlying mechanisms of neurodegenerative conditions.
---
DNLI Stock 12 Month Forecast
Average Price Target
$39.09
▲(211.47% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+27.04%
reiterated a buy rating 3 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +27.04% per trade.
---